Janssen Pharmaceutical Research & Development, LLC , 3210 Merryfield Row, San Diego, California 92121, United States.
J Med Chem. 2013 Dec 12;56(23):9369-402. doi: 10.1021/jm400386j. Epub 2013 Aug 27.
Hypoxia-inducible factor (HIF) is an oxygen-sensitive dimeric transcription factor that responds to pathophysiologically low O2 tensions via up-regulation, which leads to an orchestrated biological response to hypoxia. The HIF prolyl hydroxylase domain (PHD) enzymes are non-heme, iron-containing dioxygenases requiring for activity both molecular oxygen and 2-oxoglutarate that, under normoxia, selectively hydroxylate proline residues of HIF, initiating proteosomal degradation of the latter. The dependence of HIF protein levels on the concentration of O2 present, mediated by the PHD enzymes, forms the basis for one of the most significant biological sensor systems of tissue oxygenation in response to ischemic and inflammatory events. Consequently, pharmacological inhibition of PHD enzymes, leading to stabilization of HIF, may be of considerable therapeutic potential in treating conditions of tissue stress and injury. This Perspective reviews the PHDs and small molecule drug discovery efforts. A critical view of this challenging field is offered, which addresses potential concerns and highlights exciting possibilities for the future.
缺氧诱导因子 (HIF) 是一种氧敏感的二聚体转录因子,通过上调来应对病理生理性低氧张力,从而引发对缺氧的协调生物学反应。HIF 脯氨酰羟化酶结构域 (PHD) 酶是非血红素铁含双加氧酶,活性需要分子氧和 2-氧戊二酸,在常氧条件下,选择性地羟化 HIF 的脯氨酸残基,启动后者的蛋白酶体降解。HIF 蛋白水平对存在的氧浓度的依赖性,由 PHD 酶介导,形成了对缺血和炎症事件的组织氧合的最重要的生物传感器系统之一的基础。因此,PHD 酶的药理学抑制导致 HIF 的稳定,可能在治疗组织应激和损伤方面具有相当大的治疗潜力。本观点综述了 PHD 及其小分子药物发现的努力。提供了对这一具有挑战性的领域的批判性看法,探讨了潜在的关注点,并强调了未来令人兴奋的可能性。